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Abstract : Smoking cost the National Health Service (NHS) in England in 1996
an estimated £1.4–£1.7 billion. In 1998, in Smoking Kills, the Government
outlined an action plan for reducing smoking prevalence. This paper estimates
2006 costs and the impact of declining prevalence. Estimates are derived from
costs, service use, and attributable proportions based on current and ex-smokers’
prevalence and relative risk compared with never-smokers. Comparable 1996
costs were estimated by substituting 1996 prevalence. Smoking-attributable
hospital admissions cost the NHS an estimated £1 billion in 2006, outpatient
attendances cost £190 million, general practitioner (GP) consultations £530
million, practice nurse consultations £50 million and GP prescriptions £900
million; £2.7 billion in total. This represents 5% of adult hospital admission
costs, 4% outpatients, 11% GP and 8% practice nurse consultations and 12% of
prescription costs. Smoking accounted for 24% of respiratory disease hospital
admission costs and 16% of cancer and cardiovascular disease costs (people aged
>35 years). The 2006 cost is estimated to be 13% lower than if smoking had
remained at 1996 levels. Smoking represents a substantial cost throughout the
NHS. Significant savings are associated with a reduction in prevalence, but much
of this stems from an earlier phase of the smoking epidemic. Securing future such
savings requires further policies to reduce smoking prevalence.
1. Introduction
Current estimates for England indicate that more than one in six deaths of
adults aged 35 years and above are caused by smoking (The NHS Information
Centre for Health and Social Care, 2008). As well as reducing life expectancy,
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smoking can be associated with years of mild-to-severely debilitating ill-health,
the trauma of associated medical procedures and dependence on medication.
This represents an individual cost to smokers that is hard to quantify. In
this paper, we focus on the financial cost of smoking to the National Health
Service (NHS).
In 1998, the UK Department of Health published ‘Smoking Kills’, the first
Government White Paper specifically on tobacco control, setting out a plan of
action for reducing smoking prevalence, and hence the burden of smoking-
attributable diseases (Department of Health, 1998). The report estimated that
the cost of smoking to the NHS in England was between £1.4 and £1.7 billion in
1996 (Buck et al., 1997; Parrott et al., 1998). As part of a continuing review of
progress, we estimate the cost of smoking to the NHS 10 years later, in 2006.
These are the costs of treating smokers for diseases caused by their smoking,
taking account of hospital admissions, general practitioner (GP) consultations
and prescriptions, practice nurse consultations and outpatient attendances.
Direct comparisons with 1996 estimates are ruled out by methodological dif-
ferences and NHS developments in service provision and costing in the intervening
10 years. Instead, using the same approach as for 2006, we produce a hypothetical
estimate of the costs had smoking prevalence remained at 1996 levels.
2. Method
The methodology builds on that used to estimate mortality, morbidity and
hospital costs for London (Callum and White, 2004). Health service use among
current and ex-smokers is compared with that of never-smokers and the excess
attributed to smoking (except conditions associated with pregnancy, which are
based solely on risks of current smoking). For hospital admissions we used a
disease-based approach; for primary care and outpatients, this was not possible
and a simple measure of excess service use was used. The excess is measured in
the form of a relative risk, current or ex-smokers’ health service use relative to
that of never-smokers. Together with exposure to these risks – the proportion
who are current or ex-smokers – an estimate of the proportion attributable to
smoking can be obtained from the following standard formula:
Attributable proportion¼ ½pcurðrcur1Þ þ pexðrex1Þ=½1 þ pcurðrcur1Þ
þpexðrex1Þ
where pcur5proportion who are current smokers; rcur5 relative risk for current
smokers compared with never-smokers; pex5proportion who are ex-smokers;
and rex5 relative risk for ex-smokers compared with never-smokers [where
relative risk is for a disease (hospital admissions), or of having had a GP or
practice nurse consultation, prescription or outpatient attendance].
This proportion is then applied to total numbers of hospital admissions by disease,
GP consultations, etc, yielding an estimate of the number attributable to smoking.
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The cost to the NHS is then obtained by multiplying the attributable number by
estimates of unit cost.
Alternative approaches have been concerned with costs over the lifetime of an
individual (the life cycle approach) in which case the impact of reductions in
mortality, that is, increased life expectancy as a result of lower levels of smoking
would need to be taken into account (Sloan et al., 2004). In other words, if life
expectancy increases, ceteris paribus, more will be spent on health care in total over
a lifetime, although the annual spend per individual may well fall. Our focus is on
the extra cost to the NHS in a particular year associated with smoking, that is, we
take a cross-sectional approach. Account is not taken of any savings that may occur
in that year as a result of excess deaths of smokers in previous years.
To estimate the costs therefore involves identifying: (i) diseases caused by
smoking (for hospital admissions); (ii) current and ex-smokers’ relative risks for
these diseases and for primary care consultations, prescriptions and outpatient
visits; (iii) admitted patient care totals for diseases and total numbers of primary
care consultations, prescriptions issued and outpatient visits; (iv) NHS unit costs
for admitted patient care by disease and for primary care and outpatient visits;
and (v) the proportion of current and ex-smokers.
2.1 Hospital admission costs
2.1.1 Diseases and relative risks
Hospital admission costs are based on diseases with an established causal link;
diseases that are thought to be exacerbated by smoking are not included.
Potentially fatal diseases caused by smoking are those listed in the 2004 report
of the US Surgeon General (US Department of Health and Human Services,
2004), including several cancers, cardiovascular disease, respiratory disease and
peptic ulcer; we additionally included cancers with site unspecified.
Relative risks for each disease, separate for current and ex-smokers, are based
on the Cancer Prevention Study II (CPS-II), an American Cancer Society pros-
pective study started in 1982 of 1.2 million adults across the United States
(Stellman and Garfinkel, 1986). The relative risks used here are those derived for
the estimation of mortality in 1995 in the United Kingdom (Callum, 1998) and
in light of more recent evidence, including in our estimates, those for
cervical cancer, other heart and arterial diseases. Following the approach of Peto
et al. (1992), the relative risks are based on the years 1984–1988 and estimated
from current, ex- and never-smokers’ deaths and exposure for men and women
in five-year age groups using the Mantel–Haenszel pooling method (Rothman,
1986). This is an age-standardised approach that takes account of the very few
or zero deaths occurring in some cells, especially those related to never-smokers.
The method assumes a uniform effect within the age range for which it is calculated.
The first two years were excluded on account of the bias in short-term results of
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prospective studies; a tendency to exclude people who are sick at the outset
means lower mortality rates than in the general population, with the result
that the effects of smoking are accentuated and relative risks elevated. The
disadvantage of excluding the first two years is that the measurements of
exposure, obtained at the start of the study, become less accurate with duration
of follow-up; current smokers who quit smoking continue to be recorded as
current smokers and ex-smokers who relapse continue as ex-smokers.
Non-fatal diseases were identified from an overview (Wald and Hackshaw,
1996), and relative risks obtained from a number of sources (Independent Scien-
tific Committee on Smoking and Health, 1988; Logan, 1990; Cole et al., 1993;
Law and Hackshaw, 1997; Christen et al., 2000; Tomar and Asma, 2000). Age-
related cataract risks for women are set equal to those estimated for men (Christen
et al., 2000). Ex-smokers’ relative risks for hip fracture are assumed to be the same
as those of current smokers at the age at which they quit smoking (Law and
Hackshaw, 1997). For this, distributions by sex and age for ex-smokers according
to the age at which they quit were derived using data from the Health Survey for
England 2006 (National Centre for Social Research and University College
London Department of Epidemiology and Public Health, 2008).
To present a balanced assessment, we included diseases that can be prevented
by smoking. Relative risks were obtained for current and ex-smokers, separately
when available, otherwise combined. Risks for potentially fatal diseases were
again based on CPS-II, in the case of endometrial cancer, during 1984–1992 and
in the case of Parkinson’s disease on the CPS-II Nutrition Cohort, a follow-up
study of CPS participants started in 1992–1993 (Thacker et al., 2007). Risks for
non-fatal diseases were obtained from a number of sources (Logan, 1990; Ross
et al., 1990; Hall and Harper, 1992).
The complete list of diseases with ICD-10 (International Classification of
Diseases, 10th Revision) codes is provided in Appendix 1.
2.1.2 Hospital admissions and costs
Hospital admission estimates are based on April 2006–March 2007 Hospital
Episode Statistics (HES) for the whole of England. For ICD-10-coded disease
as primary diagnosis, hospital admissions and bed-days by sex, 10-year age
group and Healthcare Resource Group (HRG) were provided by the London
Health Observatory. This excludes diseases that appear only as a secondary
diagnosis on the hospital admission record. However, since primary diagnosis is
defined as the main reason why the patient is in hospital, whereas secondary
diagnosis is defined merely as relevant to the episode of care – although in some
cases this may add to the complexity of care – we believe most of the costs will
be captured through the use of episodes with appropriate primary diagnosis.
Moreover, the quality of coding of secondary diagnosis in HES data has been
historically poor, and so would add a greater degree of uncertainty.
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Admissions are either day cases (i.e. not staying overnight) or ordinary
inpatient admissions (i.e. staying at least one night). During a stay (also known
as a spell) in a hospital, the care of a patient may transfer from one consultant
(specialist) to another, for example, from an orthopaedic consultant to the care
of an elderly consultant, and these are recorded separately as Finished Con-
sultant Episodes (FCEs) within that one hospital stay. Hence, each hospital stay
or spell consists of one or more FCEs, most stays involving only one (88% in
2006–2007). Costings used within the NHS are spell-based, and therefore a
spell-based approach was used in this paper for the purpose of the costing
exercise. Day cases by definition are completed spells and cost estimates are
based on day case data from the admission record. Inpatient costs are based on
the overall length of stay in bed-days, or spell duration, as recorded in the
discharge record for the last FCE in the spell. Hence, inpatient costs are based
on primary diagnosis for the discharge episode. Discharge episodes include
2005–2006 admissions for spells stretching into 2006–2007, and it is assumed
here that they are balanced out by unfinished spells for admissions in
2006–2007 stretching into 2007–2008.
Day case and bed-day unit costs for diseases were derived from the NHS
FCE reference costs (Department of Health, 2006). Reference costs are not
disease-coded but based instead on HRGs. We mapped these to ICD-10 using
day case and bed-day tables of HRG by ICD-10. The disease-specific cost
estimates are a weighted sum of constituent HRG costs using proportionate
distributions of HRG within ICD-10 as weights. Day and bed-day costs for
smoking-attributable diseases were calculated for the age group to which the
smoking-attributable risks apply. Reference costs for disease groups and for
the group of all causes (i.e. all ICD codes including non-smoking related) were
calculated separately.
Reference costs for inpatient admissions are published separately for elective
and non-elective admissions. These include basic FCE costs and excess bed-day
costs, the latter associated with a longer than expected length of stay and defined
as the number of bed-days over and above pre-determined ‘trim points’. Average
costs per bed-day were calculated by combining FCE and excess bed-day elective
and non-elective reference costs.
Published reference costs for 2006–2007 use the most recent HRG coding,
HRG4. Hospital episode data, however, are coded according to the previous
version, HRG 3.5. In the absence of an HRG 3.5 to HRG 4 mapping, reference
costs for 2005–2006 were used, inflated to 2006–2007 prices using the Hospital
and Community Health Services pay and prices index. Using 2005–2006
reference costs means that 2005–2006 elective/non-elective and bed-days/excess
bed ratios are assumed to apply in 2006–2007.
For each disease, the total cost was obtained by summing day case costs
(number of day cases multiplied by average day case cost) and total bed-day
costs (number of bed-days multiplied by average cost per bed-day).
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2.2 Primary care and outpatient attendances
Primary care consultation and outpatient attendance costs are not disease-based but
are based on generic NHS service use data, and relate to all adults (aged>16 years).
2.2.1 Relative risks
Relative risk estimates were derived from data for England on the number of GP
consultations in the past two weeks, and the number involving prescriptions, number
of practice nurse consultations in the past two weeks and number of outpatient visits
in the past three months as reported in the 2006 General Household Survey (GHS)
(Office for National Statistics Social and Vital Statistics Division, 2008).
Respondents were asked the number of times they had talked to a doctor in
the past two weeks, and follow-up questions for each occasion ascertained
whether it was an NHS or private doctor, where the consultation had taken
place, on whose behalf, and for which household member if not on their own
behalf, and whether a prescription had been issued. The analysis is based on the
number of NHS GP consultations made on behalf of the respondent. This
consists of ‘own behalf’ consultations and consultations made on their behalf by
another household member, the latter constructed by re-allocating all ‘other
person’s behalf’ consultations to the appropriate household member. For the
very small number in which it seemed that the respondent had simply accom-
panied the household member, consultations were not reassigned.
Relative risks for prescriptions are based on the number of GP consultations
involving a prescription. Repeat prescriptions are said to account for more than 70%
of all prescriptions, and most are issued without talking to a GP, and hence not
counted in reports based on GP consultations. While understating the scale of pre-
scriptions issued, the assumption made here is that the relative risks for current and
ex-smokers derived from GP consultations are applicable to all prescriptions issued.
For practice nurse consultations, respondents were asked to report only those
consultations made on their own behalf. Relative risks for outpatient attendances
are based on the reported number of visits during the previous three months. These
reports are less reliable than primary care reports on two main accounts. First, three
months retrospective reporting is less reliable than two weeks. Second, misreporting
can arise from the possible confusion of outpatient attendances with other patient
care – day case admissions or non-admitted patient care such as regular day
attendance or rehabilitation services, for example.
Current and ex-smokers’ relative risks for men and women aged 16 years and
above were estimated using negative binomial regression, including age, sex, region,
National Statistics Socio-Economic Classification (NS SEC) of household reference
person and marital status including cohabitation. A negative binomial model was
selected as appropriate for these count data. Estimates and 95% confidence inter-
vals can be seen in Table 1. Estimates significantly greater than 1 (value 1 outside
the confidence interval) are used to estimate attributable proportions; otherwise,
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the relative risk is set equal to 1. Higher ex-smokers’, than current smokers’,
relative risks suggest considerable post-diagnosis smoking cessation or reporting
as such. Therefore, it is important to emphasise that the risks presented are
a means to estimate the overall impact of smoking and should not be seen as a
reflection of risks of current smoking relative to ex-smoking.
2.2.2 Total numbers and costs
GP and practice nurse consultations: Total consultations were based on QRE-
SEARCH regression estimates for England, 2006 (Hippisley-Cox et al., 2007),
using GP consultation rates by age to estimate numbers for those aged >16
years. Unit consultation costs are those, not including qualification costs, cal-
culated by the Personal Social Services Research Unit (Curtis and Netten, 2007).
Prescriptions: Total prescriptions and average prescription costs came from the
PACT (Prescribing Analysis and Cost) data on general practice prescribing in
England (Horner, 2007). The estimate of prescriptions for patients aged >16 years
assumes the Prescription Cost Analysis age structure of all prescriptions dispensed in
the community (The NHS Information Centre for Health and Social Care, 2007).
Outpatients: Total outpatient attendances were derived from the HES
2006–2007 tables (The NHS Information Centre for Health and Social Care,
2009), the number involving patients aged >16 years estimated pro rata.
Outpatient attendance unit cost is the weighted sum, using HES attendances as
weights, of first and follow-up attendance 2005–2006 NHS reference costs
(Department of Health, 2006), inflated to 2006–2007.
2.3 Smoking prevalence in 2006
Prevalence by sex and age of adult current and ex-smokers used in the estimation
of hospital admission costs was derived from the GHS 2006 data for England
(Office for National Statistics Social and Vital Statistics Division, 2008).
Table 1. Regression-based relative risk estimates for reports of health service use, England, General
Household Survey, 2006
Current smokers Ex-smokers
RR 95% CI RR 95% CI
GP consultations 1.18 1.03–1.34 1.35 1.21–1.50
GP prescriptions 1.28 1.08–1.51 1.31 1.14–1.50
Practice nurse consultations 1.11 0.91–1.37 1.37 1.18–1.60
Outpatient attendances 1.05 0.88–1.24 1.17 1.01–1.37
GP5 general practitioner; RR5 relative risk; 95% CI595% confidence interval.
Note: Values in italics indicate not significant at 0.05 level, substitute RR51, to estimate attributable
proportions.
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Since hospital admissions are based on individuals aged >15 years, whereas the
lower age limit for GHS is 16 years, we produced estimates for the age group
15–24 years by combining GHS (age: 16–24 years) with the 2006 Smoking,
Drinking and Drug Use among Young People in England Survey (age: 15 years)
data (Fuller, 2007). For smoking in pregnancy, prevalence was based on the 2005
Infant Feeding Survey (IFS) proportions who smoked throughout pregnancy –
England figures (Bolling et al., 2007). Smoking prevalence figures by sex and age
for those aged 15 years and above are shown in Table 2.
Primary care and outpatients costs are based on prevalence among all those
aged 16 years and above– 21.8% current smokers and 23.9% ex-smokers.
2.4 Cost estimates assuming 1996 smoking prevalence
Costs assuming prevalence had remained at 1996 levels were obtained by
keeping unit costs and diseases the same but substituting 2006 with 1996
attributable proportions. With prevalence at 1996 levels, we might expect there
Table 2. Cigarette smoking by sex and age, England 2006 and 1996
Age group (years)
15–241 25–34 35–44 45–54 55–64 65–74 751
2006
Men
Proportion who are current smokers 0.267 0.334 0.265 0.249 0.199 0.139 0.045
Proportion who are ex-smokers 0.071 0.161 0.203 0.238 0.394 0.469 0.579
Women
Proportion who are current smokers 0.260 0.261 0.238 0.223 0.200 0.130 0.063
Proportion who are ex-smokers 0.081 0.174 0.170 0.204 0.273 0.287 0.324
Proportion of pregnant women
who smoked throughout pregnancy2
0.326 0.114 0.09 0.09
1996
Men
Proportion who are current smokers 0.344 0.383 0.328 0.287 0.265 0.195 0.096
Proportion who are ex-smokers 0.080 0.124 0.245 0.337 0.470 0.561 0.602
Women
Proportion who are current smokers 0.361 0.331 0.295 0.303 0.253 0.221 0.096
Proportion who are ex-smokers 0.083 0.125 0.178 0.224 0.238 0.299 0.292
Proportion of pregnant women
who smoked throughout pregnancy2
0.364 0.194 0.182 0.182
Source: General Household Survey 2006 and 1996.
1Age 15 is based on 2006 Smoking, Drinking and Drug Use among Young People in England Survey
and 1996 Smoking among Secondary Schoolchildren Survey. The age group for pregnant women is all
those under 25 years and hence may include some aged under 15 years.
2Based on Infant Feeding Surveys 2005 and 1995. Age groups 35–44 and 45–54 are figures for women
aged 35 years and above.
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to have been more admissions overall. We therefore adjusted totals to include a
small increment based on the difference between 1996 and 2006 attributable
proportions. Smoking prevalence in 1996 was derived from weighted GHS 1996
data for England (Office for National Statistics Social and Vital Statistics
Division, 2002), using weights added retrospectively to the data set. Prevalence
among 15-year-olds was obtained from the 1996 Smoking among Secondary
Schoolchildren Survey (Office for National Statistics Social Survey Division,
2000) and for smoking in pregnancy from the 1995 IFS (Office of Population
Censuses and Surveys Social Survey Division, 1998). Smoking prevalence in
1996 by sex and age is shown in Table 2. Altogether, 28.5% of those aged
16 years and above were current smokers and 24.7% ex-smokers.
3. Results
Treating diseases caused by smoking cost the NHS an estimated £2.7 billion in
2006, equivalent to more than £50 million each week (hospital admission and
outpatient costs are actually based on activity during the financial year 2006–
2007). Costs are distributed approximately equally between secondary (45%)
and primary care (55%), with £1.02 billion spent on hospital admissions, £193
million on outpatient attendances, £532 million on GP consultations, £903
million on prescriptions and £54 million on practice nurse consultations.
3.1 Hospital admissions
Hospital admission costs by disease are shown in Table 3. As expected, where
smoking is the major risk factor for a disease, it accounts for most of the
treatment costs, for example, lung cancer (79%) and chronic obstructive pul-
monary disease (COPD; 81%). Where smoking is one of several risk factors,
treatment costs for high-prevalence diseases may be equally high, but the pro-
portions are lower (e.g. coronary heart disease (CHD), 20%). Although most
admission costs are for treating cancer, cardiovascular and respiratory disease,
there are notable costs for non-fatal diseases less often linked with smoking,
including hip fracture (£48.1 million) and cataracts (£7.2 million).
Lung cancer, CHD, stroke and COPD account for 56% of net smoking-
attributable admission costs, rising to 93% including other cancers, cardiovas-
cular and respiratory diseases (Table 4). Cardiovascular disease is most costly, at
£423 million, followed by cancer and respiratory disease at £273 million and
£249 million, respectively.
Compared with overall treatment costs, smoking impacts most on respiratory
disease, 24% of the total treatment costs (age >35 years) attributable to
smoking compared with 16% for cancer or cardiovascular disease (Table 5).
Just over a third of the smoking costs occur in the care of people aged ,65
years. More than half of these costs are for treating cardiovascular disease.
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Table 3. Hospital admission costs attributable to smoking by disease: England 2006–2007
Disease Age Costs (£000)
Percentage of admission costs for
the disease smoking-attributable
Caused by smoking
Cancer 276,894
Lung 351 121,277 79
Larynx1 351 16,230 82
Lip, oral cavity, pharynx 351 27,731 57
Oesophagus 351 37,579 64
Bladder 351 34,396 35
Kidney 351 7929 23
Stomach 351 10,325 23
Pancreas 351 8558 19
Cervix 351 1525 13
Myeloid leukaemia 351 7413 13
Unspecified site 351 3931 12
Cardiovascular 351 423,037
Coronary heart disease 351 181,602 20
35–64 105,477 41
651 76,124 12
Other heart disease 351 77,919 12
Cerebrovascular disease 351 75,159 12
35–64 40,511 38
651 34,648 7
Aortic aneurysm 351 33,271 53
Atherosclerosis 351 3478 13
Peripheral vascular disease 351 40,232 80
Other arterial disease 351 11,377 15
Respiratory 351 249,352
Chronic obstructive pulmonary disease 351 192,602 81
Pneumonia 351 56,750 17
Other diseases 351 90,394
Ulcer of stomach plus duodenum 351 23,089 40
Crohn’s disease 151 7919 20
Periodontal disease 151 3314 46
Age-related cataract 451 7159 9
Hip fracture 551 48,140 9
Spontaneous abortion 151 773 4
Total 1,039,677
Prevented by smoking
Parkinson’s disease 351 8300 19
Endometrial cancer 351 3955 15
Ulcerative colitis 151 3678 9
Uterine fibroids 151 3311 7
Excessive vomiting in pregnancy 151 2093 8
Gestational pre-eclampsia 151 1708 6
Total 23,045
Total admission cost (caused less prevented) 1,016,632
1Artificially high due to relatively small number of women, who have lower relative risks than men,
admitted for cancer of the larynx. Attributable proportions separately for men and women lower than
those for lung cancer.
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In fact, for CHD the burden of costs lies with people aged 35–64 years, where
smoking is a more prominent risk factor than at older ages and accounts for
41% of total CHD treatment costs. However, a greater proportion of the costs
of treating cancer and respiratory diseases occur in people aged >65 years.
The cost avoided due to the protective effect of smoking for some diseases is
approximately £23 million, not a negligible sum but by comparison a small
Table 4. Hospital admission costs due to smoking and percentage distribution by disease and age:
England, 2006–2007
Smoking Cost (£millions) Percentage of all smoking costs
15–641 651 All 151 15–64 651 All 151
Cancer
Lung Cancer 35 87 121 10 13 12
Other Cancer2 58 94 152 16 14 15
All Cancer 93 180 273 26 27 27
Cardiovascular
Coronary heart disease 105 76 182 29 12 18
Cerebrovascular disease 41 35 75 11 5 7
Other Cardiovascular 57 110 166 16 17 16
All Cardiovascular 203 221 423 56 34 42
Respiratory
COPD 36 156 193 10 24 19
Other Respiratory 18 39 57 5 6 6
All Respiratory 54 196 249 15 30 25
Other diseases2 10 61 71 3 9 7
Total 355 661 1017 100 100 100
Note: Values are rounded to the nearest million and hence may not sum to total.
1All cancer, cardiovascular and respiratory costs refer to the age group 351, for other diseases costs
refer to age groups as listed in Table 3.
2Net costs, after allowing for diseases prevented by smoking.
Table 5. Percentage of total admission treatment costs by age that are due to smoking; cancer,
cardiovascular and respiratory disease and all diseases, England 2006–2007
Percentage of total treatment costs due to smoking
35–64 651 351
Cancer 15 16 16
Cardiovascular disease 34 11 16
Respiratory disease 25 24 24
All diseases (including non-smoking related) 6 6 6
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proportion (2.2%) of the costs incurred by diseases caused by smoking. Alto-
gether, smoking accounted for 5% of all adult admission costs (aged>15 years).
3.2 Primary care and outpatients
The estimated cost of GP consultations attributable to smoking was £532 million,
11% of all adult consultation costs (aged>16 years), and GP prescriptions cost an
estimated £903 million, 12% of all costs (Table 6). Thus, one in nine pounds of
NHS expenditure on adult GP consultations and one in eight pounds on GP
prescriptions were due to smoking. Smoking accounted for an estimated 8% of
practice nurse consultation and 4% of outpatient attendance costs.
3.3 NHS costs assuming smoking prevalence had remained at 1996 levels
Assuming that smoking prevalence had not changed since 1996 and using 2006
unit costs, the cost to the NHS could have been almost £3.09 billion, compared
Table 6. Primary care and outpatient costs due to smoking: England 2006
(primary care), 2006–2007 (outpatients)
For age-group >16 years
Smoking cost
(£millions)
As percentage of all
costs (aged >16)
GP consultations 532 11
Practice nurse consultations 54 8
Prescriptions 903 12
Outpatient attendances 193 4
Total 1682
GP5 general practitioner.
Note: Values are rounded to nearest million.
Table 7. Comparison of the costs of smoking in 2006 based on smoking prevalence in 2006 and
assuming 1996 prevalence: England
Cost assuming
1996 prevalence
(£millions)
Cost using 2006
prevalence
(£millions)
Percentage decrease in costs (i.e.
costs saved because of a reduction
in smoking prevalence)
Hospital admissions 1193 1017 15
Outpatient attendances 199 193 3
GP consultations 596 532 11
Practice nurse consultations 56 54 3
Prescriptions 1043 903 13
Total cost of smoking 3087 2699 13
GP5 general practitioner.
Note: Values are rounded to the nearest million.
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to £2.70 billion (Table 7) – a difference of £388 million (13%). The largest
impact (15%) is associated with hospital admissions.
4. Discussion
This study estimates the cost of smoking to the NHS in England in 2006 to be
£2.7 billion, accounting for 5% of adult hospital admission costs, 11% of GP
consultation and 12% of GP prescription costs, 8% of practice nurse con-
sultation and 4% of outpatient costs. This represents a significant use of NHS
resources, requiring a major investment in services and patient support.
Applying 1996 smoking prevalence levels, in effect comparing the costs at a
single point in time of treating people with smoking-attributable diseases, sug-
gests that NHS costs could have been up to £388 million more.
The past decades have witnessed significant changes in smoking prevalence as
the detrimental health consequences of smoking became widely recognised,
fewer people becoming smokers and more smokers quitting, each of these
contributing to the overall impact on health costs. Based on the GHS data, in
1976 in England, for example, 46% of those aged 45–64 years were smokers;
70% had ever been smokers and 35% of these ever-smokers had quit smoking.
By 1996, current smoking among the 45–64-year-olds had fallen to 28%; 59%
were ever-smokers and significantly more, 52%, had quit. Ten years later in
2006, 22% were smokers and 49% were ever-smokers, 56% of whom had quit.
Any change in the use of NHS resources reflects the effects of changes in
prevalence over many years; for diseases with long lead times, such as lung
cancer and especially those least susceptible to the reverse effects of quitting,
ongoing reductions are largely explained by changes in smoking behaviour
decades earlier. For diseases such as CHD where quitting can reverse the risks
within a few years, the impact on costs is realised sooner.
Costs presented here address the direct effects of smoking, that is, the cost of
treating smokers for diseases caused by their smoking, and no attempt has been
made to take account of the effects of passive smoking or of maternal smoking
during pregnancy. Treatment of fire injuries due to smoking were likewise omitted
from hospital admission costs as they can include injuries of non-smokers.
NHS costs represent only a small part of the total costs to society of smoking,
taking no account of related costs such as the need to provide continuing care for
people suffering from chronic diseases as a result of smoking. The most obvious
exclusions are costs of social care and informal care for people with debilitating
heart conditions, stroke, COPD, etc. The cost of private medical care is also not
included. In addition, the full economic cost would include societal benefit pay-
ments such as disability living allowance, attendance allowance and incapacity
benefit as well as indirect costs such as the resulting loss of life or outputs. Where
the economic costs of individual diseases have been estimated, the cost to the NHS
has been shown to be a relatively small part of the total; for example, the most
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recent estimate of the cost of stroke for the United Kingdom is £9 billion, of which
just 17% is the cost to the NHS (Saka et al., 2009).
The estimates in this paper reflect what is possible with the available data. The
CPS-II relative risk data used in estimation of hospital costs, although developed
in the 1980s, remain the best available for this purpose. Admittedly, the sample
over-represents the more educated white population, but it could be argued that
this brings the advantage of greater homogeneity in composition of smokers and
non-smokers and hence estimates of relative risk are less likely to be confounded
by social class (Callum, 1998).
We are aware of issues concerning what is included in attributable health
service use as well as how primary and secondary care are costed: both of these
merit further consideration. Thus, hospital admission estimates were based on
diseases with established evidence of causality. We did not include those for
which there is accumulating evidence of a causal link such as type II diabetes and
Alzheimer’s disease, or those associated with reproduction such as infertility
(Hackshaw, 2004), or those exacerbated by smoking such as asthma, and may
therefore have slightly understated the burden of smoking on hospital admission
costs. In addition, data considerations precluded using this disease-specific
approach for primary care and outpatient estimates. Instead, they rely on generic
excess service use and thus include all diseases, covering those such as age-related
macular degeneration and psoriasis, which, though debilitating, are unlikely to
require hospitalisation, and also milder health symptoms that may be precursors
to disease. However, they also include diseases such as asthma, exacerbated
rather than caused by smoking. Furthermore, basing excess use solely on a
statistical association does risk including effects that are not all directly attri-
butable to smoking; the direction of causality between smoking and mental
health, for example, is complex.
As for the costs, some components of admitted and outpatient care were
costed separately and not included in the basic reference costs used here – for
example, critical care services and specialist care such as chemotherapy and
radiotherapy. In addition, some secondary care costs are not included, notably
accident and emergency and paramedic/ambulance costs. Reference costs are
published for these but the service delivery data do not readily lend themselves
to producing estimates comparable to those already included. And finally, our
estimates of primary care costs do not include dental health services, although
smoking is a major risk factor for periodontal disease. This was because the
banding scheme for costing dental treatments does not allow identification of
numbers and unit costs of specific treatments.
Many of these costing issues may be addressed in future through the pro-
gramme budget analysis being developed by the Department of Health. This
attempts to allocate all NHS costs including those omitted in our analysis
to ICD-based programme budget categories (PBCs) on the basis of mapping
indicative provider costs; however, these are still at an early developmental stage.
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The usefulness of these programme budget data will be enhanced as their
reliability and scope increase, although as they stand, the PBCs do not uniquely
identify each smoking-attributable disease.
Nevertheless, to illustrate and compare their use, we derived PBC-based
estimates of secondary care costs for the three disease groups that accounted
for 93% of hospital admission costs (i.e. cancer, cardiovascular disease and
respiratory disease; see Appendix 2 for the method). The estimated smoking-
attributable secondary care cost of treating these diseases is £1.6 billion; this
would imply an overall cost of smoking to the NHS of £3.1 billion. Adding
more tenuous PBC-based estimates for other diseases does not affect this total.
However, this secondary care cost estimate required the strong assumption that
proportions of PBC hospital admissions that are for smoking-related diseases
can be extrapolated for that category to all other aspects of secondary care.
5. Conclusion
We have shown that although smoking continues to represent a substantial
cost throughout the NHS, there have been significant savings associated with
a reduction in prevalence. Much of this is due to the considerable reductions
in prevalence during the 1960s and between the mid-1970s and early 1980s,
and on this account we can expect to see further savings in the coming
years. However, with prevalence levelling out around the mid-1990s and
resuming only a slow decline since 2000, the outlook beyond this could be less
promising.
Recent government policy has introduced a range of controls on the sale
and use of tobacco including the banning of smoking in enclosed work and
public places, banning various forms of advertising and increasing the age of
sale for tobacco products from 16 to 18 years. In addition, there has been
emphasis on cessation activities through a network of NHS Stop Smoking
Services and provision of pharmaceutical stop-smoking aids. (Department of
Health, 2008).
Nevertheless, maintaining the present rate of decline in prevalence is not
enough to secure additional savings on the scale already seen; this urgently
requires new policies aimed at discouraging people from becoming smokers and
getting more smokers to quit. To this end, and in the longer term, it is parti-
cularly important to focus on children and young people to prevent them from
taking up smoking in the first place. The Health Bill before Parliament in 2009
takes some steps in this direction by introducing further controls, namely the
removal of point-of-sale displays in shops, which have increasingly been used as
advertising to lure consumers, and the restriction of access to vending machines
either by location or mode of operation so that only people aged >18 years can
use them. Unfortunately, these measures are unlikely to be fully enacted until
2013 at the earliest (The Stationery Office, 2009).
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Appendix 1. Diseases included in the estimate of smoking-attributable hospital
admission costs
Disease ICD-10 Age group
Potentially fatal
Caused by smoking
Cancer
Lip, oral cavity and pharynx C00–C14 351
Oesophagus C15 351
Stomach C16 351
Pancreas C25 351
Larynx C32 351
Lung C33–C34 351
Cervix C53 351
Kidney C64–66,C68 351
Bladder C67 351
Unspecified site C80 351
Myeloid leukaemia C92 351
Cardiovascular
Coronary heart disease/ischaemic heart disease I20–125 351
Pulmonary heart disease I26–I28 351
Other heart disease I30–I51 351
Cerebrovascular disease/stroke I60–I69 351
Atherosclerosis 170 351
Aortic aneurysm I71 351
Other arterial disease I72–I781 351
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Appendix 1 (Continued)
Disease ICD-10 Age group
Respiratory
Pneumonia J10–J18 351
Chronic obstructive pulmonary disease J40–J44 351
Other
Ulcer of stomach plus duodenum K25–K27 351
Prevented by smoking
Endometrial cancer C54 351
Parkinson’s disease G20 351
Non-fatal
Caused by smoking
Age-related cataract H25 451
Peripheral vascular disease I73.9 351
Periodontal disease K05 151
Crohn’s disease K50 151
Spontaneous abortion O03 151
Hip fracture S72 551
Prevented by smoking
Uterine fibroids D25 151
Ulcerative colitis K51 151
Gestational pre-eclampsia O14 151
Excessive vomiting in pregnancy O21 151
1Except I173.9 peripheral vascular disease.
Appendix 2. Programme budget category-based secondary care costs
Here, we attempt, using the Department of Health PBC costs, to obtain a rough
idea of the scale of secondary care smoking costs had we been able to include
costs currently precluded by data limitations. For programme budgeting, all
secondary care costs are mapped to PBCs. However, these are fairly broad
ICD-based categories, and though there are PBC subcategories, it is often the
case that costs cannot be uniquely allocated and instead are recorded within a
residual ‘other’ subcategory. This exercise is based on the broad PBCs.
Provider returns for primary and secondary care PBC costs were obtained via
the Program Budget Guidance Manual excel workbook link (Department of
Health, 2007a). Final PBC costs, primary and secondary care combined, are
published in the resource accounts of the Department of Health (Department of
Health, 2007b). Resource accounts-based estimates of secondary care costs were
obtained by assuming the same proportion secondary as for provider returns.
On the basis of our cancer, cardiovascular disease and respiratory disease
hospital admission costs and PBC cancers and tumours, problems of circulation
and problems of the respiratory system secondary care costs, we obtain disease
group secondary care cost estimates. First, disease group and PBC ICD-10 codes
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were compared. PBCs are on the whole broader groupings than disease groups,
including more ICD codes. By matching PBC and disease group ICD to HES
primary diagnosis coded data, we obtained disease group hospital admissions as
a proportion of PBC hospital admissions. Making the strong assumption that
proportions of PBC hospital admissions, which are for smoking-related diseases,
can be extrapolated to all other aspects of secondary care, these proportions
multiplied by PBC costs provided disease group estimates of secondary care
costs. In the case of cardiovascular disease, some ICDs (10% of cardiovascular
admissions) are allocated to PBCs other than problems of circulation, and for
these the proportions of admissions they represent in their respective PBCs were
obtained. The total cardiovascular cost is the sum of constituent PBC costs.
Smoking-attributable costs were obtained by multiplying these totals by all-age
disease group smoking-attributable proportions.
Estimates for other diseases were obtained in similar manner, basing total
costs on their proportionate admissions profile in the respective budget category.
Diseases in the same PBC were grouped together in the calculations. These
estimates are more tenuous than disease group estimates as applying this method
to individual diseases within PBCs stretches the assumptions about propor-
tionate costs even further. However, an alternative approach, uprating hospital
admission costs by the same factor as for the three disease groups combined was
considered inappropriate as initial indications are that these, especially cardio-
vascular disease, would overstate additional costs.
Finally, for an estimate of the total cost of smoking, our hospital admission
and outpatient costs are replaced by these secondary care cost estimates.
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